GlassScriptPhysician profile
Maryjo Thomson
NPI 1982670618
$1,032.25
in general payments reported to CMS, 2019-2025
21 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $153 · 2021: $141 · 2022: $96.14 · 2023: $65.60 · 2024: $101 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $176.56 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $134.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $96.94 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $95.91 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Nevro Corp. | $81.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.61 | 2020-2022 | |
| Astellas Pharma US INC | $53.40 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.92 | 2019 | |
| Amgen INC. | $45.36 | 2024-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $44.06 | 2025 | Zepbound, Mounjaro |
| Bausch Health US, LLC | $30.87 | 2019-2020 | |
| Dynavax Technologies Corporation | $27.69 | 2019-2022 | |
| Viiv Healthcare Company | $21.01 | 2025 | Apretude |
| Althera Pharmaceuticals LLC | $15.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2020 | |
| Seqirus USA INC | $14.71 | 2020 | |
| Currax Pharmaceuticals LLC | $13.77 | 2022 | |
| Allergan, INC. | $13.24 | 2019 | |
| Sanofi Pasteur INC. | $12.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryjo Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.